Maria Florentin
A5027192832- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Virus-based gene therapy research
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- CRISPR and Genetic Engineering
- Cancer Research and Treatments
- Protein Degradation and Inhibitors
- Nanofabrication and Lithography Techniques
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- vaccines and immunoinformatics approaches
National Cancer Institute
2020-2023
Center for Cancer Research
2022-2023
National Institutes of Health
2021-2023
The accurate identification of antitumor T cell receptors (TCRs) represents a major challenge for the engineering cell-based cancer immunotherapies. By mapping 55 neoantigen-specific TCR clonotypes (NeoTCRs) from 10 metastatic human tumors to their single-cell transcriptomes, we identified signatures CD8
Abstract Purpose: Immunotherapies mediate the regression of human tumors through recognition tumor antigens by immune cells that trigger an response. Mutations in RAS oncogenes occur about 30% all patients with cancer. These mutations play important role both establishment and survival are commonly found hotspots. Discovering T-cell receptors (TCR) recognize shared mutated presented on MHC class I II molecules thus promising reagents for “off-the-shelf” adoptive cell therapies (ACT)...
Background Cellular immunotherapies using autologous tumor-infiltrating lymphocytes (TIL) can induce durable regression of epithelial cancers in selected patients with treatment-refractory metastatic disease. As the genetic engineering T cells tumor-reactive T-cell receptors (TCRs) comes to forefront clinical investigation, rapid, scalable, and cost-effective detection patient-specific neoantigen-reactive TIL remains a top priority. Methods We analyzed single-cell transcriptomic states 31...
Engineered T cells expressing tumor-specific T-cell receptors (TCRs) are emerging as a mode of personalized cancer immunotherapy that requires identification TCRs against the products known driver mutations and novel in timely fashion. We present nonviral non-next-generation sequencing platform for rapid, efficient neoantigen-specific TCR evaluation does not require use recombinant cloning techniques. The includes an innovative method TCRα detection using Sanger sequencing, pairings TCRα/β...
Abstract Adoptive cell therapy (ACT) targeting neoantigens can achieve durable clinical responses in patients with cancer. Most arise from rare mutations, requiring highly individualized treatments. To broaden the applicability of ACT neoantigens, we focused on TP53 mutations commonly shared across different cancer types. Here, describe a library T receptors (TCRs) that target among 7.3% solid cancers. These TCRs recognized tumor cells mutation- and human leucocyte antigen (HLA)-specific...
<div>Abstract<p>Adoptive cellular therapy (ACT) targeting neoantigens can achieve durable clinical responses in patients with cancer. Most arise from patient-specific mutations, requiring highly individualized treatments. To broaden the applicability of ACT neoantigens, we focused on <i>TP53</i> mutations commonly shared across different cancer types. We performed whole-exome sequencing 163 metastatic solid cancers, identified 78 who had missense and through...
Supplementary Figure from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
Supplementary Data from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
Supplementary Figure from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
Supplementary Data from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
<div>Abstract<p>Adoptive cellular therapy (ACT) targeting neoantigens can achieve durable clinical responses in patients with cancer. Most arise from patient-specific mutations, requiring highly individualized treatments. To broaden the applicability of ACT neoantigens, we focused on <i>TP53</i> mutations commonly shared across different cancer types. We performed whole-exome sequencing 163 metastatic solid cancers, identified 78 who had missense and through...
<div>AbstractPurpose:<p>Immunotherapies mediate the regression of human tumors through recognition tumor antigens by immune cells that trigger an response. Mutations in <i>RAS</i> oncogenes occur about 30% all patients with cancer. These mutations play important role both establishment and survival are commonly found hotspots. Discovering T-cell receptors (TCR) recognize shared mutated RAS presented on MHC class I II molecules thus promising reagents for...
<p>Supplementary Data Table 6.</p>
<p>Supplementary Data all</p>
<p>Supplementary Data Table 6.</p>
<div>AbstractPurpose:<p>Immunotherapies mediate the regression of human tumors through recognition tumor antigens by immune cells that trigger an response. Mutations in <i>RAS</i> oncogenes occur about 30% all patients with cancer. These mutations play important role both establishment and survival are commonly found hotspots. Discovering T-cell receptors (TCR) recognize shared mutated RAS presented on MHC class I II molecules thus promising reagents for...
<p>Supplementary Data all</p>
<h3>Background</h3> As cellular immunotherapies utilizing genetically engineered T cells become a more significant focus of clinical investigation, identification patient-specific neoantigen-reactive cell receptors (TCRs) in practical and efficient manner is top priority. Using high-dimensional single-cell analysis, we recently identified common gene expression signature anti-tumor, tumor-infiltrating lymphocytes (TIL) from patients with metastatic cancer, which included high cell-surface...